Introduction {#s1}
============

The limitations of observational cohort studies to determine causal associations between hypothesized risk factors and important chronic diseases, such as coronary heart disease (CHD), are well documented.^[@EHN252C1]^ First, because many potential risk factors are associated with a range of other predictor variables, observed associations may be because of confounding. Secondly, because CHD develops over the lifecourse,^[@EHN252C2]^ reverse causality, where early stages of atherosclerosis and/or preclinical heart disease affect risk factor levels, rather than *vice versa*, also remains a distinct possibility.

Mendelian randomization has recently been advanced as a means of dealing with both confounding and reverse causality. This approach is predicated upon the random assortment of alleles at the time of gamete formation that leads to population distributions of genetic variants that are generally independent of the environmental exposures that commonly confound epidemiological risk factors--disease associations.^[@EHN252C3]--[@EHN252C6]^ These unconfounded differences in risk factor levels should therefore translate into differences in disease occurrence if the exposure is truly causally related to the disease. Moreover, genetic variants will not be influenced by the existing cardiovascular pathology and therefore reverse causation will not distort the association between genotype and disease in the way it would distort the relationship between risk factor levels measured in adulthood and disease. Finally, genetic variants typically affect relevant protein levels throughout life, so reducing the problem of attenuation of effects (regression dilution bias) common in cohort studies with extended follow-up.

Data from the Cardiovascular Risk in Young Finns study^[@EHN252C7]^ enabled us to examine the associations of lifetime body mass index (BMI, kg/m^2^) with adult carotid intima-media thickness (CIMT), a valid preclinical marker of CHD, and atherosclerotic risk factors, such as blood pressure, lipids, and C-reactive protein, across the life course from age 3--39 years in a racially homogenous white European population. We utilized the known association of variants in the *FTO* gene with BMI^[@EHN252C8]--[@EHN252C11]^ to examine whether the Mendelian randomization approach would provide support for a causal association between lifetime BMI and atherosclerosis risk (*Figure [1](#EHN252F1){ref-type="fig"}*). Thus, individuals with A alleles in the *FTO* polymorphism rs9939609 are predisposed to higher adiposity^[@EHN252C8]^ and they have in effect been randomly allocated to somewhat higher levels of BMI than individuals with other genotypes related to lower adiposity (paths a and b). Eventually, these differences in BMI should confer differences in atherosclerosis and atherosclerotic risk (path c) factors if BMI was causally related to them and population stratification did not confound the associations.^[@EHN252C12]^ To our knowledge, this is the first Mendelian randomization study to examine the effect of lifetime BMI on atherosclerosis risk based on direct structural vascular measurement.

![The Mendelian randomization using instrumental variables regression analysis examines whether lifetime BMI, to the extent it is associated with *FTO* genotype (*path a*), predicts atherosclerosis risk (*path c*). *FTO* genotype is expected to be unrelated to confounding factors (*path b*) and thus the effects of confounding factors (*path d*) are expected to be eliminated in the analysis. Conventional regression analysis, in contrast, is open to bias because of unmeasured or imprecisely measured confounding factors.](ehn25201){#EHN252F1}

Methods {#s2}
=======

Study population {#s2a}
----------------

The Young Finns study is a multicentre follow-up study of cardiovascular risk factors in Finnish children and adolescents.^[@EHN252C7],[@EHN252C13]^ The original sample was 4320 Caucasian children and adolescents aged 3, 6, 9, 12, 15, and 18 years who were randomly sampled from five areas of Finland using the national register. The baseline examination was conducted in 1980, with response being 83% (3596 of those invited). Follow-ups were conducted in 1983, 1986, and, the latest, 2001 when the participants had reached 24--39 years of age. The 2230 individuals (1012 men and 1218 women) with full data on *FTO* polymorphism rs9939609 and BMI in childhood and adulthood formed the present analytical sample (*Figure [2](#EHN252F2){ref-type="fig"}*). Differences in the baseline characteristics of participants and non-participants were small but achieved statistical significance owing to the large numbers: BMI (17.9 vs. 17.8 kg/m^2^, *P* = 0.22); age (10.7 vs. 10.0 years, *P* \< 0.0001); and sex (55% vs. 45% female, *P* \< 0.0001). The study was conducted according to the guidelines of the Helsinki declaration, and the study protocol was approved by local ethics committees. All participants gave their full informed consent.

![Sample selection.](ehn25202){#EHN252F2}

*FTO* genotyping {#s2b}
----------------

Genomic DNA was extracted from peripheral blood leucocytes using a commercially available kit and Qiagen BioRobot M48 Workstation according to the manufacturer's instructions (Qiagen Inc., Hilden, Germany). We genotyped *FTO* single nucleotide polymorphism (SNP) rs9939609 by employing the 5′ nuclease assay and fluorogenic allele-specific TaqMan MGB probes,^[@EHN252C14]^ using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The samples were pipetted using an automated TECAN Freedom EVO-100 instrument (Tecan Group Ltd, Männedorf, Switzerland). The nucleotide sequences of the primers and probes used in the polymerase chain reaction (PCR) were deduced from published sequences deposited in the GenBank and Celera databases and synthesized by Applied Biosystems. The PCR containing genomic DNA, 1× Universal PCR Master Mix, 900 nM of each primer and 200 nM of each probe were performed in 384-well plates using the standard protocol in a total volume of 5 µL. Endpoint fluorescence was measured post-PCR and genotype calling carried out by the allelic discrimination analysis module (ABI Prism SDS software, ABI, Foster City, CA, USA). Random duplicates were used as quality control. All genotypes were analysed in the Department of Clinical Chemistry at Tampere University Hospital and University of Tampere.

Body mass index and other life course atherosclerotic risk factors {#s2c}
------------------------------------------------------------------

Life course measures were based on repeated assessments in 1980 (participant age range 3--18 years), 1983 (6--21 years), 1986 (9--24 years), and 2001 (24--39 years), except C-reactive protein, which was assessed in 1980 and 2001 only. Measurements of weight (kg) and height (mm) were obtained using standard research protocols and were used to calculate BMI (weight in kg/height^2^ in m).^[@EHN252C15]^ Measurements of blood pressure were taken with the participant in the sitting position after 5 min rest with a mercury sphygmomanometer (for the 3 year olds with ultrasound device, Arteriosonde 1020, Roche) in 1980, 1983, and 1986 and with a random zero sphygmomanometer (Hawksley & Sons Ltd, West Sussex, UK) in 2001.^[@EHN252C16],[@EHN252C17]^ Readings to the nearest even number of millimetres of mercury were performed at least three times on each subject; the average of the systolic blood pressure measurements was used in the analysis.

In 1980, 1983, 1986, and 2001, all blood samples were taken after an overnight fast and analysed in duplicate in the same laboratory on each time occasion.^[@EHN252C7]^ Standard enzymatic methods were used for serum total cholesterol, HDL-cholesterol and triglycerides, and plasma glucose concentrations. LDL-cholesterol concentration was calculated using the Friedewald formula.^[@EHN252C18]^ In 2001, we assessed serum high-sensitive C-reactive protein using an automated analyser (Olympus AU400, Olympus, USA) and a highly sensitive turbidimetric immunoassay kit (CRP-UL-assay, Wako Chemicals, Neuss, Germany). Serum C-reactive protein samples taken in 1980 were stored at −20°C and analysed in 2005 using the same method as in 2001. During the storage, the samples were not thawed or refrozen.

Carotid intima-media thickness and adulthood atherosclerotic risk factors {#s2d}
-------------------------------------------------------------------------

In 2001--2002, ultrasound studies were performed using Sequoia 512 ultrasound mainframes (Acuson, Mountain View, CA, USA) to measure CIMT. The measurement has previously been described in detail.^[@EHN252C7],[@EHN252C19]^ In brief, the image was focused on the posterior (far) wall of the left carotid artery. A minimum of four measurements of the common carotid far wall were taken approximately 10 mm proximal to the carotid bifurcation to derive mean carotid IMT. The digitally stored scans were manually analysed by one reader blinded to subjects' details (M.J.). The between-visit coefficient of variation of IMT measurements was 6.4%.

Several additional assessments were carried out in 2001.^[@EHN252C20]^ Waist circumference (mm, measured in duplicate at the level of the twelfth rib or level with the navel in thin subjects) and hip circumference (mm) were obtained to calculate waist--hip ratio. Standard enzymatic methods were used for plasma glucose concentrations. Serum insulin was measured by microparticle enzyme immunoassay kit (Abbott Laboratories, Diagnostic Division, Dainabot). Insulin resistance was estimated according to the homeostasis model as the product of fasting glucose and insulin divided by the constant 22.5, i.e. the HOMA index.^[@EHN252C21]^ Serum apolipoproteins A-1 and B were analysed immunoturbidometrically (Orion Diagnostica, Espoo, Finland).

Parental factors and adult lifestyle factors {#s2e}
--------------------------------------------

Parental socioeconomic position was measured in 1980 using parental occupational status as classified by Statistics Finland and categorized as manual vs. non-manual.^[@EHN252C22]^ Where socioeconomic position differed between parents, data on the parent with the higher occupational status were used. Parental BMI in 1980 was calculated from self-reported height and weight.

The participant's own adult socioeconomic position was measured in 2001 by occupational status and categorized as for parental socioeconomic position. Educational attainment was categorized as academic; secondary education but not academic; and comprehensive school as the highest level of education. Information on adult smoking (status and pack-years of tobacco smoking) and alcohol consumption (units per week) was obtained by questionnaire in 2001. One unit of alcohol (12 g) was equal to a glass of wine, a single 4 cL measure of spirits or a 33 cL bottle of beer.^[@EHN252C20]^

Statistical analysis {#s2f}
--------------------

Statistical significance in all tests was inferred at a two-tailed *P* \< 0.05. The following tests were performed.

### Preliminary genetic analyses {#s2f1}

We tested the Hardy--Weinberg equilibrium at *FTO* SNP locus, on a contingency table of observed vs. predicted genotypic frequencies, with an exact test to evaluate whether genotyping error, biological selection bias, or other population non-homogeneity was likely in our data. The genotype frequencies in the *FTO* polymorphism were in Hardy--Weinberg equilibrium (*P* \> 0.20), thus supporting the integrity of our genetic data.

### Test of genotype--phenotype associations {#s2f2}

We constructed lifetime phenotype measures for BMI, height, systolic blood pressure, total cholesterol, HDL- and LDL-cholesterol, and C-reactive protein by calculating age-standardized *z*-scores (mean = 0, standard deviation = 1) for each age and for men and women separately and then averaged across ages within each measure and participant. We used the logarithm of C-reactive protein to correct for its positively skewed distribution. There was no strong evidence of *FTO* polymorphism × sex interaction on any of the phenotype measures (all *P* \> 0.11), thus the main analysis was conducted for men and women in combination. We used linear regression analysis to study the age- and sex-adjusted associations of the *FTO* genotype (per A allele) with phenotype measures. Since our analyses are all hypothesis driven and hence equivalent to a candidate gene approach, we used conventional alpha levels to detect statistically significant associations without adjusting for multiple testing. These analyses were performed with Statistical Analysis System (SAS, version 9.1).

### Instrumental variables regression analysis {#s2f3}

As in previous studies using the Mendelian randomization approach,^[@EHN252C23]--[@EHN252C31]^ we performed an instrumental variables regression analysis to examine if the *FTO* polymorphism was associated with CIMT and atherosclerotic risk factors through its association with BMI levels. We compared the results from the instrumental variable estimates of the association between lifetime BMI and phenotype measures (i.e. path c in *Figure [1](#EHN252F1){ref-type="fig"}*) to those from standard linear regression using the Durbin form of the Durbin--Wu--Hausman statistic.^[@EHN252C32]^ We used the *F*-statistics from the first-stage regressions to evaluate the strength of the instruments, i.e. path a in *Figure [1](#EHN252F1){ref-type="fig"}* (values \>10 are taken to indicate sufficient strength to ensure the validity of instrumental variable methods).^[@EHN252C33],[@EHN252C34]^ Instrumental variable regression analysis was performed with Stata (version 9.2, Stata Institute, TX, USA).

An additional analysis with a simulated data set was carried out to examine the change in precision of the results from the instrumental variable regression analyses if our sample size was substantially larger. First, we filled the missing values in the baseline sample (*n* = 3596) by multivariate imputation method of ICE in Stata software, with missing-at-random assumptions \[*n* = 1410 (39%) had some missing data\]. In addition to all the variables in the analyses, the imputation process included baseline predictors of dropout from the cohort, such as BMI (available from all but one baseline participant). We imputed two independent copies of the complete baseline data and treated them as one artificially created simulated data set with a sample size of 7192. Both standard and instrumental variables regression analyses were then run with this large simulated data set. To examine whether the obtained estimates were robust, we repeated this procedure five times, thus creating five independent simulated data sets, and compared estimates between the simulations.

Results {#s3}
=======

Characteristics of the study population are shown in *Table [1](#EHN252TB1){ref-type="table"}*. Variation in *FTO* (rs9939609) was not associated with potential confounding factors, such as age, sex, socioeconomic circumstances, education, or risk behaviours (*Table [2](#EHN252TB2){ref-type="table"}*) supporting the assumption that the variation in the *FTO* genotype is independent of potential confounding factors (path b in *Figure [1](#EHN252F1){ref-type="fig"}*). In contrast, lower parental socioeconomic position and participant's lower educational attainment were associated with higher lifetime BMI (*P* \< 0.05), demonstrating that observed BMI is affected by potential confounding factors (path d in *Figure [1](#EHN252F1){ref-type="fig"}*).

###### 

Characteristics of study sample

                                               Female   Male                   
  -------------------------------------------- -------- --------------- ------ ---------------
  Mean age at baseline (year)                  1218     10.7 (5.0)      1012   10.7 (5.0)
                                                                               
  *FTO* genotype (rs9939609) (%)                                               
   TT                                          420      34.5            367    36.3
   TA                                          592      48.6            495    48.9
   AA                                          206      16.9            150    14.8
  Mother's BMI (kg/m^2^)                       1185     24.0 (3.8)      986    23.9 (3.7)
  Father's BMI (kg/m^2^)                       1069     25.5 (3.1)      873    25.4 (3.1)
                                                                               
  BMI in childhood and adolescence (kg/m^2^)                                   
   Age 3                                       173      15.5 (1.2)      148    15.6 (1.0)
   Age 6                                       371      15.6 (1.7)      290    15.5 (1.7)
   Age 9                                       562      16.6 (2.3)      465    16.6 (2.1)
   Age 12                                      600      18.3 (2.7)      485    18.1 (2.6)
   Age 15                                      601      20.2 (2.5)      503    20.0 (2.5)
   Age 18                                      554      21.2 (2.6)      429    21.5 (2.7)
                                                                               
  Adult measures (age 24--39)                                                  
   Carotid IMT (mm)                            1207     0.573 (0.084)   1004   0.593 (0.100)
   BMI (kg/m^2^)                               1218     24.5 (4.6)      1012   25.7 (4.1)
   Waist--hip ratio                            1218     0.79 (0.06)     1012   0.90 (0.06)
   Waist circumference (mm)                    1218     794 (114)       1012   898 (108)
   Height (cm)                                 1218     166.0 (59.6)    1012   179.5 (65.4)
   Systolic BP (mmHg)                          1205     116.0 (12.4)    1000   129.3 (13.5)
   TC (mmol/L)                                 1218     5.05 (0.91)     1012   5.26 (1.04)
   HDL-cholesterol (mmol/L)                    1218     1.39 (0.30)     1010   1.16 (0.28)
   LDL-cholesterol (mmol/L)                    1218     3.14 (0.77)     1010   3.42 (0.92)
   TG (mmol/L)                                 1218     1.16 (0.67)     1012   1.54 (1.00)
   Log C-reactive protein (mmol/L)             1218     −0.09 (1.82)    1012   −0.54 (1.65)
   Glucose (mmol/dL)                           1218     4.92 (0.74)     1012   5.23 (0.92)
   Insulin (mmol/dL)                           1218     7.83 (5.92)     1011   7.72 (5.80)
   HOMA index                                  1218     1.77 (1.80)     1011   1.87 (2.01)
   Apolipoprotein A-1 (g/L)                    1218     1.56 (0.26)     1012   1.40 (0.21)
   Apolipoprotein B (g/L)                      1218     0.99 (0.24)     1012   1.14 (0.27)

###### 

Associations between *FTO* polymorphism rs9939609 and potential confounding factors

                                                      *n*    \% or mean (SD) by *FTO* genotype   Change^a^ (95% CI)   *P* for trend^a^                           
  --------------------------------------------------- ------ ----------------------------------- -------------------- ------------------ ----------------------- ------
  Sex (% of men)                                      2230   46.6                                45.5                 42.1               −0.02 (−0.05, 0.01)     0.19
  Age (years)^b^                                      2230   10.6 (4.9)                          10.6 (5.0)           11.0 (5.1)         0.15 (−0.15, 0.45)      0.32
  Parental socioeconomic position (% of manual)^b^    2171   38.4                                40.6                 39.5               0.01 (−0.02, 0.04)      0.62
  Own adult socioeconomic position (% of manual)^c^   1918   32.4                                33.1                 31.8               0.00 (−0.03, 0.03)      0.88
  Education (% of academic)^c^                        2218   16.8                                19.9                 19.0               0.001 (−0.002, 0.005)   0.21
  Smoking (% of smokers)^c^                           2170   24.6                                24.1                 25.3               0.00 (−0.02, 0.03)      0.77
  Pack-years among smokers^c^                         507    10.2 (7.9)                          9.2 (6.5)            9.1 (7.2)          −0.34 (−1.17, 0.48)     0.41
  Alcohol consumption (units per week)^c^             2199   6.3 (9.2)                           5.8 (8.0)            7.0 (8.1)          −0.12 (−0.61, 0.37)     0.64

^a^Adjusted for age and sex.

^b^Participants at age 3--18.

^c^Measured at age 24--39.

Gene-phenotype associations {#s3a}
---------------------------

*FTO* polymorphism explained 0.4% of the variation in lifetime BMI. Each additional copy of the A allele in the *FTO* gene was associated with higher lifetime BMI, with higher maternal BMI and, more weakly, paternal BMI (*Table [3](#EHN252TB3){ref-type="table"}*). *FTO* polymorphism was also associated with higher lifetime systolic blood pressure, but no association was found with lipids or C-reactive protein. The association between *FTO* polymorphism and lifetime systolic blood pressure attenuated after adjustment for lifetime BMI (adjusted change per A allele, 0.05; 95% CI, −0.01, 0.10; *P* = 0.11), suggesting that adiposity as indexed by BMI at least partially mediates this association.

###### 

Associations between *FTO* polymorphism rs9939609 and phenotypes across the life course and in adulthood

                                           *n*    Mean (SD) by *FTO* genotype   Change^a^ (95% CI)   *P* for trend^a^                           
  ---------------------------------------- ------ ----------------------------- -------------------- ------------------ ----------------------- -------
  Parental phenotype                                                                                                                            
   Mother's BMI, kg/m^2^                   2171   23.7 (3.7)                    23.9 (3.7)           24.5 (4.1)         0.36 (0.14, 0.58)^b^    0.001
   Father's BMI, kg/m^2^                   1940   25.3 (3.1)                    25.6 (3.1)           25.6 (3.0)         0.14 (−0.06, 0.34)^b^   0.16
                                                                                                                                                
  Lifetime phenotype^c^ (mean *z*-score)                                                                                                        
   BMI                                     2230   −0.07 (0.99)                  0.02 (1.01)          0.11 (0.98)        0.09 (0.03, 0.15)       0.003
   Systolic BP                             2204   −0.06 (1.02)                  0.01 (0.97)          0.10 (1.03)        0.08 (0.02, 0.14)       0.01
   TC                                      2226   −0.01 (1.00)                  0.01 (0.98)          −0.05 (1.04)       −0.01 (−0.07, 0.05)     0.70
   HDL-cholesterol                         2224   0.01 (1.01)                   −0.02 (0.99)         0.03 (1.01)        0.00 (−0.06, 0.06)      0.95
   LDL-cholesterol                         2224   −0.01 (0.99)                  0.01 (0.99)          −0.05 (1.05)       −0.01 (−0.07, 0.05)     0.69
   TG                                      2228   −0.02 (1.06)                  0.02 (0.97)          −0.06 (0.96)       −0.01 (−0.07, 0.05)     0.85
   C-reactive protein^d^                   2133   −0.02 (1.02)                  −0.01 (0.98)         0.07 (1.00)        0.04 (−0.02, 0.10)      0.22
                                                                                                                                                
  Adult phenotype^e^                                                                                                                            
   CIMT, mm                                2211   0.578 (0.087)                 0.582 (0.095)        0.587 (0.097)      0.003 (−0.001, 0.009)   0.14
   BMI, kg/m^2^                            2230   24.9(4.5)                     25.1 (4.3)           25.4 (4.5)         0.28 (0.02, 0.54)       0.04
   Waist--hip ratio                        2230   0.840 (0.080)                 0.841 (0.083)        0.845 (0.082)      0.003 (−0.000, 0.007)   0.07
   Waist circumference, mm                 2230   837 (123)                     842 (122)            848 (124)          6.5 (−0.1, 13.0)        0.05
   Height, cm                              2230   172.1 (8.9)                   172.3 (9.1)          171.6 (9.6)        0.1 (−0.3, 0.5)         0.60
   Glucose, mmol/dL                        2230   5.04 (0.71)                   5.03 (0.65)          5.19 (1.41)        0.06 (0.01, 0.11)       0.01
   Insulin, mmol/dL                        2229   7.50 (4.79)                   8.01 (6.58)          7.69 (5.71)        0.18 (−0.17, 0.54)      0.31
   HOMA index                              2229   1.73 (1.44)                   1.86 (2.05)          1.88 (2.28)        0.08 (−0.03, 0.20)      0.13
   Apolipoprotein A-1, g/L                 2230   1.50 (0.25)                   1.48 (0.24)          1.50 (0.27)        −0.01 (−0.02, 0.01)     0.43
   Apolipoprotein B, g/L                   2230   1.06 (0.27)                   1.06 (0.26)          1.04 (0.27)        −0.01 (−0.02, 0.01)     0.35

Note P for all interactions with sex ≥ 0.11.

^a^Adjusted for age and sex.

^b^Analysis is additionally adjusted for parental age.

^c^Measured at ages 3, 6, 9, 12, 15, 18, 24, 27, 30, 33, 36, and 39 years. Only those participants with data measured in adulthood (age 24--39) and at least once between ages 3--18 included in the analysis.

^d^Standardized after logarithmic transformation.

^e^Measured at age 24--39.

Of the adulthood outcomes, a greater number of A alleles was associated with higher BMI (although less strongly than with lifetime BMI), larger waist circumference, and higher fasting glucose levels. Adjustment for BMI and waist circumference had little effect on the association between *FTO* polymorphism and fasting glucose (adjusted change per A allele 0.05; 95% CI, 0.01, 0.10; *P* = 0.03). A greater number of A alleles was weakly associated with greater CIMT and higher insulin resistance. Progression of atherosclerosis is more rapid in men than in pre-menopausal women. In sex-specific analysis, each additional copy of A allele was associated with a CIMT increase of 0.009 mm (95% CI, 0.000, 0.017; *P* = 0.049) in men. This figure was 0.000 mm (95% CI, −0.006, 0.007; *P* = 0.95) in women (*P* for sex interaction = 0.11; for all other genotype associations, *P* for sex interaction exceeded 0.2). Adjustment for BMI and waist circumference slightly reduced the effect of *FTO* genotype on CIMT in men (per A allele change, 0.008; 95% CI, −0.001, 0.016; *P* = 0.08).

Standard regression analysis and instrumental variables regression analysis {#s3b}
---------------------------------------------------------------------------

The standard regression analysis suggests positive associations of lifetime BMI with adult CIMT, lifetime systolic blood pressure, adult glucose, and adult insulin resistance (*Table [4](#EHN252TB4){ref-type="table"}*, upper panel). In the instrumental variables regression analysis with *FTO* polymorphism as the instrument for unconfounded lifetime BMI levels (path a in *Figure [1](#EHN252F1){ref-type="fig"}*), all the effects of BMI on CIMT and other phenotypes are in the same direction but less precisely estimated (*P*-values range between 0.02 and 0.15). In general, the effects appeared larger in the instrumental analysis than in the standard regression analysis, but only for adult fasting glucose does the difference in effect sizes between the two analyses reach conventional statistical significance. The wide confidence intervals in the instrumental variables regression analysis suggest that our data, despite the relatively large sample size, had limited power for the instrumental variable analyses (i.e. path a in *Figure [1](#EHN252F1){ref-type="fig"}* was relatively weak). Indeed, *F*-values in the first-stage regression testing the strength of instruments were \<10 (range, 7.5--9.2). Running these analyses with *FTO* haplotypes as instruments did not solve this problem as the strength of instrument was not improved (see [Supplementary material online](http://eurheartj.oxfordjournals.org/cgi/content/full/ehn252/DC1), Appendix 1).

###### 

Comparison of the association of lifetime BMI with carotid intima-media thickness (CIMT), blood pressure, glucose, and insulin resistance obtained from ordinary least squares linear regression to that obtained from the instrumental variables regression analysis^a^

  Outcome                            *n*    Beta (95% CI) for outcome per 1 SD increase in sex- and age-standardized lifetime BMI z-score   *P* for difference in effect size between the two analytical approaches   
  ---------------------------------- ------ ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- --------
  Study population                                                                                                                                                                                                    
   Adult CIMT, mm                    2211   0.011 (0.007 to 0.015)                                                                          0.048 (−0.016 to 0.112)                                                   0.23
                                            *P* \< 0.0001                                                                                   *P* = 0.15                                                                
   Lifetime systolic BP, z-score     2204   0.36 (0.32 to 0.40)                                                                             0.95 (0.15 to 1.74)                                                       0.09
                                            *P* \< 0.0001                                                                                   *P* = 0.02                                                                
   Adult glucose, mmol/dL            2230   0.08 (0.05 to 0.12)                                                                             0.67 (−0.02 to 1.35)                                                      0.04
                                            *P* \< 0.0001                                                                                   *P* = 0.06                                                                
   Adult HOMA index                  2229   0.47 (0.40 to 0.55)                                                                             0.94 (−0.34 to 2.22)                                                      0.46
                                            *P* \< 0.0001                                                                                   *P* = 0.15                                                                
                                                                                                                                                                                                                      
  Simulated data^b^                                                                                                                                                                                                   
   Adult CIMT, mm                    7192   0.013 (0.011 to 0.016)                                                                          0.061 (0.020 to 0.101)                                                    0.01
                                            *P* \< 0.0001                                                                                   *P* = 0.003                                                               
   Lifetime systolic BP, *z*-score   7192   0.31 (0.29 to 0.33)                                                                             0.60 (0.30 to 0.89)                                                       0.04
                                            *P* \< 0.0001                                                                                   *P* \< 0.0001                                                             
   Adult glucose, mmol/dL            7192   0.09 (0.07 to 0.11)                                                                             0.72 (0.32 to 1.12)                                                       0.0002
                                            *P* \< 0.0001                                                                                   *P* \< 0.0001                                                             
   Adult HOMA index                  7192   0.55 (0.51 to 0.60)                                                                             0.89 (0.14 to 1.64)                                                       0.37
                                            *P* \< 0.0001                                                                                   *P* = 0.02                                                                

^a^In instrumental variables regression analysis *FTO* polymorphism rs9939609 acts as an instrument for the unconfounded lifetime effect of BMI on CIMT and risk factors.

^b^*Post hoc* analysis with artificially generated larger sample (sample size equals two times baseline cohort).

The lower panel of *Table [4](#EHN252TB4){ref-type="table"}* shows the results from the standard and instrumental variables regression analyses using simulated data corresponding to ours, but the sample size increased two-fold to that we had at the baseline (i.e. *n* = 2 × 3596). In such data, *F*-value in the first-stage regression is 31.6; all of the associations of lifetime BMI with CIMT and atherosclerotic risk factors were now robust in instrumental variables regression analysis and for all outcomes except HOMA index these associations were of greater magnitude compared with those in the standard regression analyses. We repeated these analyses with five independently simulated data sets. The associations in instrumental variables regression analysis and standard regression analysis remained across all of the simulations repeated five times, whereas the difference in the magnitude of the associations between the two analyses was consistently replicated only for adult glucose (see [Supplementary material online](http://eurheartj.oxfordjournals.org/cgi/content/full/ehn252/DC1), Appendix 2).

Discussion {#s4}
==========

This study took advantage of the robust association between *FTO* polymorphism rs9939609 and BMI to conduct a Mendelian randomization analysis on the effect of lifetime BMI on CIMT and various atherosclerotic risk factors in a cohort of young adults. As expected, standard regression analysis showed lifetime BMI to be associated with greater adult CIMT, higher lifetime systolic blood pressure, higher adult fasting glucose, and higher HOMA index. When *FTO* polymorphism was used as an instrument for non-confounded BMI levels, similar or larger effects of lifetime BMI on all these phenotypes were found, but for statistically robust findings our sample size would need to be considerably larger.

Utility of the Mendelian randomization approach {#s4a}
-----------------------------------------------

At least three issues suggest that Mendelian randomization approach may add to the evidence from conventional cohort studies in testing the contribution of lifetime BMI to atherosclerosis risk. First, confirming previous studies, *FTO* polymorphism was associated with BMI (path a in *Figure [1](#EHN252F1){ref-type="fig"}*).^[@EHN252C8]--[@EHN252C11]^ This association was stronger for lifetime BMI than adult BMI, which is, as would be expected, given that genotypes should have life-long influence on risk factor levels.^[@EHN252C35]^ Our analysis using the *FTO* genotype as an instrument for life-long BMI levels is therefore likely to be less biased by attenuation by errors than those based on a single measurement of BMI. In addition, *FTO* polymorphism was associated with parental BMI, as would be expected, given that offspring share all genes with their parents (50% with each parent). The slightly stronger association with maternal than paternal BMI may reflect intrauterine influences of maternal obesity programming increased life-long obesity risk in the offspring, non-paternity generating attenuated paternal associations, or random variation in associations.^[@EHN252C36]--[@EHN252C38]^

Secondly, *FTO* polymorphism was not associated with factors such as sex, age, early or adult socioeconomic circumstances, educational attainment, smoking, or alcohol consumption. Thus, these common confounding factors are unlikely to distort the instrumental variables analysis of the effect of BMI on atherosclerosis risk (path b in *Figure [1](#EHN252F1){ref-type="fig"}*), as has been demonstrated previously.^[@EHN252C39]^ Thirdly, as the *FTO* genotype determines the increased risk of higher BMI levels from early life onwards, reverse causality where subclinical atheroma affects risk factor levels was largely eliminated.

A full understanding of the function of the *FTO* gene is undergoing further exploration. However, both high BMI and type 2 diabetes contribute to atherosclerotic vascular changes,^[@EHN252C40]--[@EHN252C43]^ and an additive effect of the *FTO* variant rs9939609 on BMI has been replicated in at least 13 unselected independent population studies with 38 759 participants.^[@EHN252C8]^ In the Avon Longitudinal Study of Parents and Children (ALSPAC) offspring, the variant was shown to have a specific association with fat mass.^[@EHN252C8]^ In genome wide studies, the *FTO* gene has been identified to predispose to type 2 diabetes via an effect on BMI.^[@EHN252C8]^ Furthermore, it has been shown that the *FTO* gene is associated with insulin resistance, hyperglycaemia, dyslipidaemia, and hypertension, as one would predict based on observational evidence of the association of BMI with these outcomes,^[@EHN252C44]^ and of randomized trials of the effect of weight change interventions on these outcomes.^[@EHN252C44]^ These findings suggest that greater adiposity is indeed causally related to these outcomes and that the observational studies for these associations provide valid estimates of effect. Furthermore, these findings provide some support that *FTO* polymorphism is a valid instrument for adiposity. If it were not a valid instrument of adiposity, then one would not expect such accurate prediction of the causal effect of adiposity on outcomes that are generally widely accepted as being causally related to greater adiposity,^[@EHN252C45]^ and that alter in relation to changes in BMI in randomized controlled trials of drug and surgery treatments that reduce BMI.^[@EHN252C46]--[@EHN252C48]^

Study limitations {#s4b}
-----------------

Limitations of Mendelian randomization testing have been discussed in detail previously.^[@EHN252C5]^ It is possible that *FTO* has other direct phenotypic effects in addition to those on BMI, and it is these that influence the outcomes. Furthermore, the expression of *FTO* during early-life development could trigger a canalizing response that would mitigate the effects of increased adiposity. Studies utilizing additional independent genetic variants related to BMI, and investigations of when, during development, the variants begin to influence adiposity, could help resolve these issues. It could be argued that, as adjustment for BMI did not abolish the *FTO*-outcome associations, this suggests that there are indeed alternative pathways linking *FTO* to the outcomes. However, it must be remembered that even the repeat measures of BMI utilized in our lifetime BMI score will not be an accurate indicator of true lifetime adiposity, and a residual effect of *FTO* after adjustment for our lifetime BMI measure would be expected even if the entire effect of *FTO* was mediated through adiposity.

In this study, the wider confidence intervals for effect estimates from instrumental variables analysis compared with those obtained from the standard regression models demonstrate a drawback. Body mass index is a complex trait, and the small proportion of variation in BMI explained by the genetic instrument based on a single gene leads to the much lower precision of the instrumental variables analysis estimates compared with the estimates from standard regression models. Thus, the instrumental variable estimates are typically less efficient than the standard regression estimates if there is no confounding, reverse causality, or measurement error, but unlike the standard regression estimators the instrumental variables estimates should remain consistent when these are present. Besides supporting the role of BMI as a contributing factor to CIMT and various atherosclerotic risk factors, our findings suggest that the true influence of BMI on these factors might be underestimated in cohort studies. However, larger samples and/or stronger genetic instruments are needed before this conclusion can be convincingly supported by statistically robust results after correction for multiple testing. Furthermore, as the function of *FTO* is not fully known, we cannot be certain that the *FTO* polymorphism conferred effect on atherosclerosis risk factors only through adiposity.

Conclusion {#s5}
==========

Mendelian randomization approach has different strengths and limitations than conventional analysis. We found evidence that genetic variants in the *FTO* gene were not related to potential confounding factors; that they were strongly associated with lifetime BMI levels; and that the findings on the effects of lifetime BMI on CIMT and atherosclerosis risk factors as obtained from Mendelian randomization and standard regression models were converging. These results suggest that Mendelian randomization approach with *FTO* genotype data indeed have the potential of complementing existing evidence on the effects of lifetime BMI on atherosclerosis risk in large cohorts of young adults.
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